Related references
Note: Only part of the references are listed.Sorafenib in Metastatic Thyroid Cancer: A Systematic Review
Ligy Thomas et al.
ONCOLOGIST (2014)
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
Martin Franz Sprinzl et al.
HEPATOLOGY (2013)
Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Jonathan Welti et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Near-infrared fluorescence imaging of gastrin releasing peptide receptor targeting in prostate cancer lymph node metastases
Quan-Yu Cai et al.
PROSTATE (2013)
The transferrin receptor and the targeted delivery of therapeutic agents against cancer
Tracy R. Daniels et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2012)
Regulation of iron transport and the role of transferrin
Konstantinos Gkouvatsos et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2012)
FDG-PET as a pharmacodynamic biomarker for early assessment of treatment response to linifanib (ABT-869) in a non-small cell lung cancer xenograft model
Sarah R. Mudd et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
Development of a Hypoxia-Selective Near-Infrared Fluorescent Probe for Non-invasive Tumor Imaging
Bahaa Gamal Mohamed Youssif et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2012)
Tumor glucose metabolism imaged in vivo in small animals with whole-body photoacoustic computed tomography
Muhammad Rameez Chatni et al.
JOURNAL OF BIOMEDICAL OPTICS (2012)
Incongruity of Imaging Using Fluorescent 2-DG Conjugates Compared to 18F-FDG in Preclinical Cancer Models
Jen-Chieh Tseng et al.
MOLECULAR IMAGING AND BIOLOGY (2012)
In Vivo Imaging and Quantification of Carbonic Anhydrase IX Expression as an Endogenous Biomarker of Tumor Hypoxia
Bagna Bao et al.
PLOS ONE (2012)
Cancer metabolism: current perspectives and future directions
C. Munoz-Pinedo et al.
CELL DEATH & DISEASE (2012)
Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts
Rogier P. J. Schroeder et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
The multikinase inhibitor Sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE2 in murine macrophages
Justin P. Edwards et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2010)
Early Detection of Response to Experimental Chemotherapeutic Top216 with [18F]FLT and [18F]FDG PET in Human Ovary Cancer Xenografts in Mice
Mette Munk Jensen et al.
PLOS ONE (2010)
Tumor cell metabolism imaging
Christian Plathow et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states
Nieves Gonzalez et al.
CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY (2008)
Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature
Weibo Cai et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Uptake of a fluorescent deoxyglucose analog (2-NBDG) in tumor cells
RG O'Neil et al.
MOLECULAR IMAGING AND BIOLOGY (2005)
Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate
V Ntziachristos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Metabolism-enhanced tumor localization by fluorescence imaging:: in vivo animal studies
Y Chen et al.
OPTICS LETTERS (2003)
Increased frequency of gastrin-releasing peptide receptor gene mutations during colon-adenocarcinoma progression
SC Glover et al.
MOLECULAR CARCINOGENESIS (2003)
Molecular imaging of cancer with positron emission tomography
SS Gambhir
NATURE REVIEWS CANCER (2002)
BAY 43-9006: Early clinical data in patients with advanced solid malignancies
SJ Hotte et al.
CURRENT PHARMACEUTICAL DESIGN (2002)